Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag for thrombocytopenia before hepatectomy after conversion therapy for liver cancer
ChiCTR2400084748Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lusutrombopag in Thrombocytopenia and hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Percentage of patients with preoperative platelet count >=75 x 10^9/L and >20% increase from pretreatment. Planned start May 2024; status: not yet recruiting.
02
Drugs
lusutrombopag
03
Conditions
Thrombocytopeniahepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400084748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084748.